Transaction DateRecipientSharesTypePriceValue
11th August 2020Eyal Rubin246,146Grant/award etc.$0.00
11th August 2020Dror Bashan447,927Grant/award etc.$0.00
7th April 2020Aharon Schwartz64,000Open or private purchase$2.43$155,264.00
9th March 2020Aharon Schwartz112,200Sale back to the issuer$0.00
Protalix Biotherapeutics
Protalix Biotherapeutics logo

Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 9/10.

Protalix Biotherapeutics, Inc. engages in the development and commercialization of recombinant therapeutic proteins. It offers Taliglucerase alfa injections under the brand name Elelyso. The company's drugs also include Oral Glucocerebrosidase for potential treatment of Gaucher disease; therapeutic proteins for Fabry disease, and immune diseases.

Ticker: PLX
Sector: Health Services
Industry: Services to the Health Industry
SEC Central Index Key (CIK): 1006281
Employees: 196
Exchange: NYSE American
Auditor Opinion:

Disclosure Language changes
Red Flags
Cash at Carrying Value: $5 M (0%)
Inventory, Net: $11 M (0%)
Other Assets, Current: $3 M (57%)
Assets, Current: $54 M (66%)
Property, Plant and Equipment, Net: $5 M (-9%)
Assets: $72 M (57%)
Liabilities, Current: $42 M (5%)
Other Liabilities, Noncurrent: $124 Th (-75%)
Liabilities: $106 M (-7%)
Stockholders' Equity (Parent): $35 M (0%)
Liabilities and Equity: $72 M (57%)
Research and Development: $9 M (-52%)
Operating Income/Loss: $2 M (-8%)
Other Income, net: $2 M (-61%)